These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 25511894)

  • 21. Differential levels of p75NTR ectodomain in CSF and blood in patients with Alzheimer's disease: a novel diagnostic marker.
    Jiao SS; Bu XL; Liu YH; Wang QH; Liu CH; Yao XQ; Zhou XF; Wang YJ
    Transl Psychiatry; 2015 Oct; 5(10):e650. PubMed ID: 26440538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Essential Features and Use Cases of the Cerebrospinal Fluid Proteome Resource (CSF-PR).
    Guldbrandsen A; Farag YM; Lereim RR; Berven FS; Barsnes H
    Methods Mol Biol; 2019; 2044():377-391. PubMed ID: 31432427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease.
    Majbour NK; Vaikath NN; van Dijk KD; Ardah MT; Varghese S; Vesterager LB; Montezinho LP; Poole S; Safieh-Garabedian B; Tokuda T; Teunissen CE; Berendse HW; van de Berg WD; El-Agnaf OM
    Mol Neurodegener; 2016 Jan; 11():7. PubMed ID: 26782965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
    Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
    Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
    J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medial temporal lobe atrophy increases the specificity of cerebrospinal fluid biomarkers in Alzheimer disease with minor cerebrovascular changes.
    Zhang Y; Londos E; Minthon L; Wattmo C; Blennow K; Liu HJ; Bronge L; Aspelin P; Wahlund LO
    Acta Radiol; 2009 Jul; 50(6):674-81. PubMed ID: 19455444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomarkers in Alzheimer's disease drug development.
    Cummings JL
    Alzheimers Dement; 2011 May; 7(3):e13-44. PubMed ID: 21550318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Challenge of Disease-Modifying Therapies in Parkinson's Disease: Role of CSF Biomarkers.
    Paolini Paoletti F; Gaetani L; Parnetti L
    Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32092971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients.
    Di Domenico F; Pupo G; Giraldo E; Badìa MC; Monllor P; Lloret A; Schininà ME; Giorgi A; Cini C; Tramutola A; Butterfield DA; Viña J; Perluigi M
    Free Radic Biol Med; 2016 Feb; 91():1-9. PubMed ID: 26675344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
    Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
    Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease.
    Tateno F; Sakakibara R; Kawai T; Kishi M; Murano T
    Alzheimer Dis Assoc Disord; 2012; 26(3):213-6. PubMed ID: 22037599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
    Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach.
    van Dijk KD; Teunissen CE; Drukarch B; Jimenez CR; Groenewegen HJ; Berendse HW; van de Berg WD
    Neurobiol Dis; 2010 Sep; 39(3):229-41. PubMed ID: 20451609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alzheimer disease: MRI and CSF biomarkers in AD--accuracy and temporal change.
    Prins ND; van Swieten JC
    Nat Rev Neurol; 2010 Dec; 6(12):650-1. PubMed ID: 21131912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials.
    Olsson B; Schott JM; Blennow K; Zetterberg H
    Expert Rev Neurother; 2017 Aug; 17(8):767-775. PubMed ID: 28604243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.
    Kaerst L; Kuhlmann A; Wedekind D; Stoeck K; Lange P; Zerr I
    J Alzheimers Dis; 2014; 38(1):63-73. PubMed ID: 23948928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease.
    Isobe C; Murata T; Sato C; Terayama Y
    Life Sci; 2005 Aug; 77(15):1836-43. PubMed ID: 15935398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
    Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
    Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebrospinal fluid Aβ42 levels and APP processing pathway genes in Parkinson's disease.
    Bekris LM; Tsuang DW; Peskind ER; Yu CE; Montine TJ; Zhang J; Zabetian CP; Leverenz JB
    Mov Disord; 2015 Jun; 30(7):936-44. PubMed ID: 25808939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial.
    Wang T; Huang Q; Reiman EM; Chen K; Li X; Li G; Lin Z; Li C; Xiao S
    J Clin Psychopharmacol; 2013 Oct; 33(5):636-42. PubMed ID: 23948786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.